KAEL-GemVax announced results from its Phase 2 study of vaccination with the telomerase peptide GV1001 after chemoradiotherapy in Stage III non-small cell lung cancer (NSCLC) patients. The primary objective was immunologic response, with toxicity and time to progress as secondary objectives.

Twenty-three subjects (20 evaluable per protocol) with inoperable stage IIIA/B NSCLC were enrolled at three different centers in Norway. The study population received radiotherapy (2Gy x30) and weekly docetaxel (20mg/m2), followed by GV1001 vaccination. Subjects with metastatic disease were excluded. The study reports that vaccination with GV1001 is well tolerated, immunizing the majority of NSCLC patients and establishing durable T-cell memory. The authors conclude that the survival advantage observed for immune responders warrants a randomized trial.

For more information visit www.kaelgemvax.com.